HOLOGIC, INC. (NASDAQ:HOLX) Files An 8-K Regulation FD DisclosureItem 7.01.
On March6, 2018, Hologic, Inc. (the “Company”) completed the previously announced redemption of its 2.00% convertible senior notes due 2042 (the “Notes”). to the terms of the indenture governing the Notes (the “Indenture”), holders of the Notes also had the right to surrender the Notes for conversion at any time prior to 5 p.m. ET on March5, 2018. Notes in aggregate original principal amount of $201,150,000 were validly surrendered for conversion and will be settled in accordance with the terms of the Indenture and the Company’s previously announced election to settle all conversions of the Notes entirely in cash.
The remaining $4,867,000 in original principal amount of Notes was redeemed by the Company today at an aggregate redemption price of $4,868,703.45, or $1,000.35 per $1,000 in original principal amount, which includes accreted principal and accrued and unpaid contingent interest to, but not including, the redemption date.
About HOLOGIC, INC. (NASDAQ:HOLX)
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.
